MedTrace Logo

Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation

NCT01150162 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2013-02-04

No results posted yet for this study

Summary

A Prospective Randomized, Multi-center study to assess the Safety and Efficacy of Mucosta (Rebamipide), in combination with Omeprazole as adjuvant therapy in Gastric Ulcer Patients.

Conditions

  • Gastric Ulcer

Interventions

DRUG

Rebamipide and Omeprazole

open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks

DRUG

Omeprazole

open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks

Sponsors & Collaborators

  • Otsuka Pakistan Limited

    lead INDUSTRY

Principal Investigators

  • Dr. Laeeque Ahmed, Asst. Professor · Dr. Ziauddin University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-06-30
Completion
2012-08-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01150162 on ClinicalTrials.gov